GT Biopharma
GTBP
36 hedge funds and large institutions have $5.63M invested in GT Biopharma in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
29% more capital invested
Capital invested by funds: $4.36M → $5.63M (+$1.27M)
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
6% more funds holding
Funds holding: 34 → 36 (+2)
0.38% more ownership
Funds ownership: 0.27% → 0.65% (+0.38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.64M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$466K |
| 3 |
BFS
Baskin Financial Services
Toronto,
Ontario, Canada
|
+$252K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$167K |
| 5 |
Renaissance Technologies
New York
|
+$76.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$44K |
| 2 |
Millennium Management
New York
|
-$36.8K |
| 3 |
State Street
Boston,
Massachusetts
|
-$34.8K |
| 4 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$31K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$26K |
GTBP Hedge Fund Activity: Q4 2022 in Review
36 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q4 2022, worth a combined $5.63M — up 29% from $4.36M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GTBP positions and 7 closed out — a net gain of 2 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $5.64M. The largest seller was Virtu Financial, exiting entirely with an estimated $44K sold.
- 36 institutional investors held GT Biopharma (GTBP) as of Q4 2022, up from 34 in Q3 2022.
- Funds reported $5.63M of GT Biopharma stock for Q4 2022, up 29% quarter-over-quarter.
- 9 funds opened new GT Biopharma positions in Q4 2022 and 7 closed out, a net change of +2 holders.
- The largest GT Biopharma buyer in Q4 2022 was Armistice Capital, an estimated $5.64M added.
- The largest GT Biopharma seller in Q4 2022 was Virtu Financial, an estimated $44K sold.
Based on aggregated 13F filings for Q4 2022.